Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ.

PLoS One. 2012;7(5):e36669. doi: 10.1371/journal.pone.0036669. Epub 2012 May 10.

2.

Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA 3rd, Smith JA Jr, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ.

Am J Pathol. 2015 May;185(5):1385-95. doi: 10.1016/j.ajpath.2015.01.014.

3.

When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression.

DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM.

Urol Oncol. 2013 Aug;31(6):802-11. doi: 10.1016/j.urolonc.2011.07.017. Epub 2011 Sep 15. Review.

4.

High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

Li W, Liu M, Feng Y, Huang YF, Xu YF, Che JP, Wang GC, Zheng JH.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2430-40. eCollection 2013.

5.

FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.

Warrick JI, Kaag M, Raman JD, Chan W, Tran T, Kunchala S, Shuman L, DeGraff D, Chen G.

Virchows Arch. 2017 Sep;471(3):337-345. doi: 10.1007/s00428-017-2190-3. Epub 2017 Jul 18.

PMID:
28721490
6.

Immunohistochemical determination of ETS-1 oncoprotein expression in urothelial carcinomas of the urinary bladder.

Sari A, Calli A, Gorgel SN, Altinboga AA, Kara C, Dincel C, Cakalagaoglu F.

Appl Immunohistochem Mol Morphol. 2012 Mar;20(2):153-8. doi: 10.1097/PAI.0b013e31821ba035.

PMID:
21623185
7.

CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.

Omran OM.

J Environ Pathol Toxicol Oncol. 2012;31(3):203-12.

PMID:
23339695
8.

DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study.

Tsai MC, Li WM, Huang CN, Ke HL, Li CC, Yeh HC, Chan TC, Liang PI, Yeh BW, Wu WJ, Lim SW, Li CF.

Oncotarget. 2016 Nov 29;7(48):78918-78931. doi: 10.18632/oncotarget.12912.

9.

Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.

Makboul R, Refaiy A, Abdelkawi IF, Hameed DA, Elderwy AA, Shalaby MM, Merseburger AS, Hussein MR.

Pathol Res Pract. 2016 May;212(5):385-92. doi: 10.1016/j.prp.2016.02.008. Epub 2016 Feb 9.

PMID:
26916953
10.

E-cadherin expression in invasive urothelial carcinoma.

Sun W, Herrera GA.

Ann Diagn Pathol. 2004 Feb;8(1):17-22.

PMID:
15129905
11.

α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.

Liu J, Cai M, Chen J, Liao Y, Mai S, Li Y, Huang X, Liu Y, Zhang J, Kung H, Zeng Y, Zhou F, Xie D.

Eur J Cancer. 2014 Mar;50(4):840-51. doi: 10.1016/j.ejca.2013.11.038. Epub 2014 Jan 2.

PMID:
24388773
12.

Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.

Paner GP, Barkan GA, Mehta V, Sirintrapun SJ, Tsuzuki T, Sebo TJ, Jimenez RE.

Am J Surg Pathol. 2012 Mar;36(3):432-42. doi: 10.1097/PAS.0b013e31823fe49c. Review.

PMID:
22301493
13.

New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.

Gabriel U, Li L, Bolenz C, Steidler A, Kränzlin B, Saile M, Gretz N, Trojan L, Michel MS.

Mol Carcinog. 2012 Nov;51(11):907-15. doi: 10.1002/mc.20860. Epub 2011 Oct 4.

PMID:
21976419
14.

Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway.

Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, Trink B, Kihara K.

Cancer Res. 2009 Dec 15;69(24):9263-70. doi: 10.1158/0008-5472.CAN-09-1188.

15.

E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.

Oliveira PA, Colaço A, De la Cruz LF, Lopes P, Lopes C.

J Exp Clin Cancer Res. 2006 Sep;25(3):425-32.

PMID:
17167984
16.

E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma.

Lim MG, Adsay NV, Grignon DJ, Osunkoya AO.

Mod Pathol. 2011 Feb;24(2):241-7. doi: 10.1038/modpathol.2010.187. Epub 2010 Sep 3.

17.

PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells.

Ismail AF, Oskay Halacli S, Babteen N, De Piano M, Martin TA, Jiang WG, Khan MS, Dasgupta P, Wells CM.

Biochem J. 2017 Mar 24;474(8):1333-1346. doi: 10.1042/BCJ20160875.

PMID:
28232500
18.

E-cadherin÷CD44 immunophenotype in the epithelial-mesenchymal transition of bladder urothelial carcinomas.

Stepan AE, Pirici D, Bălăşoiu M, Novac MB, Drocaş AI, Ciurea RN, Stepan D, Gheonea DI, Simionescu CE.

Rom J Morphol Embryol. 2015;56(1):85-91.

19.

Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis.

Kaur S, Momi N, Chakraborty S, Wagner DG, Horn AJ, Lele SM, Theodorescu D, Batra SK.

PLoS One. 2014 Mar 26;9(3):e92742. doi: 10.1371/journal.pone.0092742. eCollection 2014.

20.

Dual role of TGFBR3 in bladder cancer.

Liu XL, Xiao K, Xue B, Yang D, Lei Z, Shan Y, Zhang HT.

Oncol Rep. 2013 Sep;30(3):1301-8. doi: 10.3892/or.2013.2599. Epub 2013 Jul 8.

PMID:
23835618

Supplemental Content

Support Center